Log in to search using one of your social media accounts:

 

Systemic AL Amyloidosis Myopathy: Presentation, Diagnostic Pitfalls and Outcome
Amyloid myopathy is a rare syndrome with sparse data on its presentation and outcome. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Eli Muchtar, Daniele Derudas, Michelle Mauermann, Teerin Liewluck, Angela Dispenzieri, Shaji Kumar, David Dingli, Martha Lacy, Francis Buadi, Suzanne Hayman, Prashant Kapoor, Nelson Leung, Rajshekar Chakraborty, Wilson Gonsalves, Stephen Russell, John Lus Source Type: research

Clinical Features and Outcomes of Plasmacytoma: a National Cancer Database Study (2000 – 2011)
Most of the studies of plasmacytoma are derived from small, single tertiary institution experiences. There is a paucity of large studies to assess real-world outcomes and survival patterns in this disease within the community. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Gaurav Goyal, Wilson Gonsalves, Ronald Go Source Type: research

High Throughput Chemical Library  Screens Identify a Novel Small Molecule Checkpoint Inhibitor that Activates Anti-myeloma T Cells
Multiple myeloma (MM) remains an incurable plasma cell malignancy. Checkpoint inhibitors represent a revolutionary approach that empowers the immune system to defeat cancer. PD-L1 and PD-L2 expressed on tumor cells engage PD-1 on T cells to block antitumor responses. Here, we identified a novel small molecule PI3K/p110- δ inhibitor that downregulates PD-L1/PD-L2 on MM cells and enhances T cell anti-myeloma activity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: James J. Driscoll, Irim Aslam, Ehsan Malek Source Type: research

Identifying the Genomic Landscape of Pediatric Myelodysplastic Syndromes (MDS)
MDS is uncommon in children (incidence of ∼2 cases/million) and carries a poor prognosis. Much has been learned about adult MDS using high-throughput sequencing, which has identified recurrent mutations in genes that regulate epigenetics and RNA transcript splicing. Much less is understood about pediatric MDS, and many recurrent mutations found in adults are not common in children. Furthermore, the clinical presentation, bone marrow morphology, and cytogenetic abnormalities are also different when comparing adult and pediatric MDS, suggesting disparate underlying mechanisms. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Jason Schwartz, Michael Walsh, Jina Ma, Tami Lamprecht, Raul Ribeiro, Jeffery Klco Tags: Myelodysplastic Syndromes Source Type: research

Feasibility of Allogeneic Stem Cell Transplantation After Azacitidine in  Patients with High Risk Myelodysplastic Syndromes or Low-Blast Count Acute Myeloid Leukemias: the Experience of the BMT-AZA Multicenter Prospective Study
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative approach for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Since azacitidine approval for the treatment of high-risk MDS and low-blast count AML, patients experienced reduction of therapy-related complications and satisfactory overall response rate. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Maria Teresa Voso, Marianna Criscuolo, Giuseppe Leone, Alfonso Piciocchi, Luana Fianchi, Stella Santarone, Anna Candoni, Arianna Masciulli, Elisa Cerqui, Alfredo Molteni, Carlo Finelli, Matteo Parma, Antonella Poloni, Nicola Cascavilla, Francesco Spina, A Source Type: research

The Role of Hypomethylating Agents (Hma) in Early Myeloid Relapses After Allogenic Hematopoietic Stem Cell Transplant (HSCT)
To retrospectively analyze the outcome of patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) early relapsing after HSCT. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: F élix López Cadenas, Ana Martín López, Javier Carrillo Checa, Oriana López Godino, Oscar Ferré, Luís García Martín, Estefanía Pérez López, Lourdes Vázquez López, María Díez-Campelo, Lucía López Corral, Maria Consuelo Del Cañizo Fernán Source Type: research

International Sentinel Site Surveillance of Patients with Transfusional Hemosiderosis Treated with Deferasirox in Actual Practice Setting
The oral iron chelator deferasirox is indicated for treatment of chronic iron overload (IOL) resulting from blood transfusions in patients aged ≥2 years. Multiple clinical studies have established the efficacy and safety of deferasirox in transfusion-dependent patients with IOL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Amal El-Beshlawy, Baba Inusa, David Beneitez, Blanca Xicoy, Maria Soledad Duran Nieto, Andreas Bruederle, Amin Azmon, Geralyn Gilotti, Mohsen Elalfy Source Type: research

Myelodysplastic Syndromes with Bone Marrow Fibrosis: a Distinct Entity
The WHO 2008 MDS classification recognizes MDS with fibrosis (MDS-F) as an unclassified subtype and there remains little data pertaining to the treatment and outcomes in the MDS-F. The primary objective of this study is to examine a large MDS population to determine the relationship between BMF and survival outcomes in the context of new risk stratification models. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Megan Melody, Najla Al Ali, Ling Zhan, Hanadi Ramadan, Eric Padron, David Sallman, Jeffery Lancet, Alan List, John Bennett, Rami Komrokji Source Type: research

ASXL1 Frameshift Mutations Drive Inferior Outcomes in CMML without Negative Impact in MDS
In myelodysplastic syndromes (MDS), mutation of ASXL1 was least predictive of inferior outcomes and type of mutation was not analyzed. In contrast, mutational analysis in chronic myelomonocytic leukemia (CMML) has identified ASXL1 mutation as the only mutation to be independently predictive of inferior survival when including only nonsense and frameshift mutations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: David Sallman, Jinming Song, Thomas Cluzeau, Christine Vaupel, Najla Al Ali, Jeffrey Lancet, Jeff Hall, Alan List, Eric Padron, Rami Komrokji Source Type: research

Population-Based Cause of Death Among Patients with Myelodysplastic Syndromes
Myelodysplastic Syndromes (MDS) are more prevalent among older patients and are associated with poor overall survival; while many patients die of complications directly related to MDS, many die another concurrent condition, independent of or exacerbated by MDS. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Andrew Brunner, Gabriela Hobbs, Philip Amrein, Karen Ballen, Timothy Graubert, Amir Fathi Source Type: research

A Phase II Trial of Low-Dose Hypomethylating Agents in Patients with Low- or Intermediate-1-Risk MDS
The outcome of patients with lower-risk myelodysplastic syndrome (MDS) is heterogeneous. Whether hypomethylating agents (HMAs) can alter the natural history of this disease is unknown. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Nicholas Short, Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Koji Sasaki, Mikkael Sekeres, Rami Komrokji, David Steensma, Amy DeZern, Gail Roboz, Tapan Kadia, Gautam Borthakur, Courtney DiNardo, Darla Miller, Zeev Estrov, Naveen Pemmaraju, Naval Da Source Type: research

T-Cell Large Granular Lymphocyte Proliferation (LGL) in Patients with Myelodysplastic Syndromes (MDS): Not an Innocent Bystander?
LGL associated with MDS has been reported. However, clinicopathological features, prognostic, and predictive factors in those patients (pts) diagnosed with both LGL and MDS is not well studied. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Christa Roe, Najla Ali, P.K. Epling-Burnette, Janice Bennett, Eric Padron, David Sallman, Lubomir Sokol, Jeffrey Lancet, Alan List, Rami Komrokji Source Type: research

Racial Disparities in Patients with Myelodysplastic Syndrome (MDS): is There Really a Difference?
Little is known about racial disparities amongst patients with MDS. The incidence of MDS is higher in Caucasians, who represent the majority of patients included on clinical trials. We explored the differences in disease features and outcomes between Caucasians, African Americans (AA), and Hispanics. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Hanadi Ramadan, Amanda Cameron, Najla Al Ali, Eric Padron, David Sallman, Jeffrey Lancet, Alan List, Rami Komrokji Source Type: research

An International Multicenter Project on Secondary Myelofibrosis
Polycythemia vera (PV) and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms that can progress to secondary myelofibrosis (SMF). Information on SMF biology and outcome is scant. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Barbara Mora, Paola Guglielmelli, Mario Cazzola, Margherita Maffioli, Alessandro Rambaldi, Marianna Caramella, Rami Komrokji, Jason Gotlib, Jean Jacques Kiladjian, Francisco Cervantes, Timothy Devos, Nicola Vianelli, Valerio De Stefano, Marco Ruggeri, Ric Tags: Myeloproliferative Neoplasms Source Type: research

Comparing Eras in Myelofibrosis: Changing Patterns of Treatment Before and After FDA-Approval of Ruxolitinib
On November 16th, 2011, ruxolitinib was approved by the FDA for treatment of intermediate and high-risk myelofibrosis (MF). Before this, a variety of treatments were used for myelofibrosis, with variable efficacy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Andrew Kuykendall, Najla Al Ali, Chetasi Talati, Eric Padron, David Sallman, Jeffrey Lancet, Alan List, Kenneth Zuckerman, Rami Komrokji Source Type: research

Clinical Characteristics of Patients with Primary or Post-Polycythemia Vera/Post-Essential Thrombocytopenia Myelofibrosis and Deletion 13q
Deletion 13q [del(13q)] occurs rarely in patients with primary myelofibrosis (PMF) and as a single cytogenetic abnormality confers a favorable prognosis. Little is known about the prognostic impact of del(13q) in patients with post-polycythemia vera/post-essential thrombocytopenia myelofibrosis (PET/PPV-MF). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Lucia Masarova, Kate Newberry, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek Source Type: research

Does Therapy-Related Myelofibrosis Exist? Analysis of 1100 Myelofibrosis Cases from a Single Institution
The association between prior other malignancies (OM) and myelofibrosis (MF) as well as the existence of therapy-related myelofibrosis (t-MF) are largely unknown. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Lucia Masarova, Prithviraj Bose, Hagop Kantarjian, Srdan Verstovsek Source Type: research

Does Occurrence of Other Malignancy After Essential Thrombocythemia and Polycythemia Vera Influence their Rate of Transformation to Myelofibrosis?
Other malignancies (OM) were reported to be increased in patients with essential thrombocythemia (ET) and polycythemia vera (PV). The effect of coexistent OM on the rate of disease transformation to MF is unknown. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Lucia Masarova, Sherry Pierce, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek Source Type: research

Superior Lethal Activity of Novel BRD4-Degrading Proteolysis Targeting Chimera (PROTACs) versus  BET Protein Bromodomain Inhibitor (BETi) Against Post-Myeloprofilerative Neoplasm (MPN) Secondary AML Cells
Myeloproliferative neoplasm, myelofibrosis (MPN-MF), exhibits increased JAK-STAT signaling and often progresses ( ∼15-20%) to AML (sAML). JAK inhibitor (JAK-I) ruxolitinib (Rux) or standard induction chemotherapy is only modestly active against sAML. sAML cells commonly exhibit JAK2V617F mutation, as well as mutations in TP53, TET2, ASXL1, IDH1&2, SRSF2, RUNX1, MYC, PTPN11, NRAS and SETBP1. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Kapil Bhalla, Dyana Saenz, Warren Fiskus, Taghi Manshouri, Baohua Sun, Christopher Mill, Srdan Verstovsek Source Type: research

Virtual Patient Simulation: Improving Management of Polycythemia Vera Patients No Longer Responding to Cytoreductive Therapy
For many patients with polycythemia vera (PV), their disease is suboptimally managed due to loss of response to frontline cytoreductive therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Simon Cooper, Emily Van Laar, Richard Caracio, Douglas Blevins Source Type: research

The Effect of Polycythemia Vera on Hearing Functions
Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm which is characterized by clonal proliferation causing the accumulation of morphologically normal red and white blood cells, platelets and their precursors. Bilateral or unilateral sensorineural hearing loss, acute hearing loss and vertigo may be the first presenting findings of PV. The aim of this study was to determine the effect of PV on hearing functions and the frequency of impairment in hearing functions seen in affected patient population. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Esma Dogan, Mustafa Uslu, Hatice Kiper, G üray Saydam, Mehmet Ogut, Mahmut Tobu Source Type: research

Update: a Novel Stratification of Myelofibrosis Patients by Likelihood of Response to JAK2 Inhibitors
Current prognostic models for MF (e.g. DIPSS plus) have uncertain value in predicting clinical response or survival during treatment with JAK2 inhibitors. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Kamal Menghrajani, Philip Boonstra, Alissa Weber, Cecelia Perkins, Krisstina Gowin, Huong (Marie) Nguyen, Ruben Mesa, Jason Gotlib, Moshe Talpaz Source Type: research

Somatic Next Generation Sequencing Panels Identify Potentially Pathogenic Germline Variants in Genes Associated with Hereditary Myeloid Malignancies
Hereditary myeloid malignancy syndromes (HMMS) predispose to myelodysplastic syndrome, leukemias, myeloproliferative neoplasms, and bone marrow failure. Genes whose germline variants are implicated in HMMS are often included in next generation sequencing (NGS) panels designed to detect somatic mutations and guide prognostication. These panels cannot distinguish germline mutations from somatic mutations when analyzing DNA derived from leukemia cells. We hypothesized that a 53 gene NGS panel ordered for assessment of mutations in newly diagnosed hematologic malignancies could identify patients with germline mutations causati...
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Michael Drazer, Allison West, Madina Sukhanova, Simone Feurstein, Matthew Jones, Jeremy Segal, Jane Churpeck, Lucy Godley Source Type: research

Myelodysplastic/Myeloproliferative Neoplasms Unclassified (MDS/MPN-U) Overlap: Impact of Hypomethylating Agents?
The 2008 World Health Organization classification recognized a unique overlap category that combines features of MDS and myeloproliferative neoplasms. The least well characterized of the 4 overlap diseases is a rare entity known as MDS/MPN Unclassifiable (MDS/MPN-U), comprising (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Kaitlin Hendrix, Najla Al Ali, Eric Padron, David Sallman, Alan List, Jeffrey Lancet, Rami Komrokji Source Type: research

Clinical Response to Total Skin Electron Beam Therapy in Primary Cutaneous T-Cell Lymphoma
Total skin electron beam therapy (TSEB) is an integral treatment modality in primary cutaneous T-cell lymphoma (pCTCL), a type of non-Hodgkin lymphoma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Erin Dean, G. Grass, Kamran Ahmed, Michael Montejo, Lubomir Sokol, Sungjune Kim Tags: Non-Hodgkin Lymphoma Source Type: research

Small Fiber Neuropathy is More Frequent in Chronic Lymphocytic Leukemia and NonHodgkin Lymphoma Patients
Small fiber neuropathy (SFN) is difficult to diagnose because it cannot be demonstrated in conventional nerve conduction studies. Cutaneous Silent Period (CSP) could be used as an objective method for evaluating small nerve fibers. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Gulsum Emel Pamuk, Muhammet Maden, Aslan Tekatas, Omer Nuri Pamuk Source Type: research

A Novel In Situ Vaccine: Intratumoral Flt3L and Poly-ICLC with Low-Dose Radiotherapy
Lymphomas are the 5th most common cancer in the United States, 40% of these cases are indolent non-Hodgkin's lymphoma (iNHL) and are incurable with standard therapy. In a previous trial of in situ vaccination (ISV) in iNHLs, in which intratumoral CpG, the TLR9 agonist, was combined with low dose radiation to induce a systemic immune response against tumor, induction of tumor-specific CD8 T cell responses and durable clinical remissions of patients ’ untreated sites of disease was seen in some patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Thomas Marron, Nina Bhardwaj, Linda Hammerich, Fiby George, Seunghee Kim-Schulze, Tibor Keler, Tom Davis, Elizabeth Crowley, Andres Salazar, Joshua Brody Source Type: research

Single Institution Experience in Management of Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL-NOS)
PTCL constitutes an umbrella of malignancies classified under Non-Hodgkin's Lymphoma (NHL). Due to the overall poor response to treatment, a multidisciplinary treatment approach including hematopoietic stem cell transplantation (HSCT) is considered. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Susmitha Apuri, Bigling Yue, Zhenjun Ma, Ling Zhang, Lubomir Sokol Source Type: research

Serum Albumin as Prognostic Factor for Overall Survival in Rearranged MYC and BCL2/BCL6 Positive Double Hit Diffuse Large B Cell Lymphomas
Double hit lymphomas (DHL) [rearranged c-MYC and BCL2/BCL6 by FISH analysis in diffuse large B cell lymphomas (DLBCL)] represent a subset of DLBCL with poor overall survival (OS). Several prognostic scores have been tested to clinically stratify these patients with the double hit score  (DHS) being the most recently developed model (Petrich 2014). We explored the role of serum albumin (SA) in the prognosis of DHL as previously shown in DLBCL (Dalia 2013). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Chetasi Talati, Andrew Kuykendall, Jori Kaplan, Jose Sandoval-Sus, Samir Dalia, Bijal Shah, Celeste Bello, Paul Chervenick, Ernesto Ayala, Frederick Locke, Mohamed Kharfan-Dabaja, Eduardo Sotomayor, Lubomir Sokol, Julio Chavez Source Type: research

Preclinical Study of Combination of Antifolate Agents with Palbociclib Isethionate to Treat Mantle Cell Lymphoma with or without P53 Deficiency
Mantle cell lymphoma (MCL) carries an unfavorable prognosis and easily relapse and resistance especially MCL with P53 deficiency so that requires new treatment strategies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Huihan Wang, Xiaobin Wang, Richard Jones, Isere Kuiatse, Hua Wang, Robert Orlowski Source Type: research

BRAF and MAP2K1 Genes Mutation in Splenic Marginal Zone Lymphoma and Hairy Cell Leukemia
Splenic marginal zone lymphoma (SMZL), a specific type of small B-cell lymphoma. Hairy cell leukemia (HCL) has characteristics to distinguish it from other B-cell lymphomas. Sequencing revealed that mutation in BRAF gene detected in 100% of patients HCL and demonstrate constitutive activation of RAF-MEK-ERK-cascade. These findings make a significant contribution to the diagnosis of issues and allow distinguishing HCL from similar B-cell lymphomas, such as SMZL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Hunan Julhakyan, Igor Yakutik, Lyubov Al-Radi, Bella Biderman, Tatyana Moiseeva, Andrey Sudarikov, Valeriy Savchenko Source Type: research

Single Center Experience in Diagnosis of Hepatosplenic T-cell Lymphoma
Hepatosplenic T-cell lymphoma (HSTL) is a rare form of non-Hodgkins lymphoma with involvement of the liver, spleen and bone marrow. Diagnosis and treatment of HSTL are still difficult. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Natalya Chernova, Hunan Julhakyan, Yulia Vinogradova, Yulia Sidorova, Marina Sinitsyna, Alla Kovrigina, Evgeniy Zvonkov, Elena Parovichnikova, Valeriy Savchenko Source Type: research

Treatment of Pediatric B-cell Non-Hodgkin Lymphoma in Croatia
The feasibility of treating children in Croatia with B-cell non-Hodgkin lymphoma (B-NHL) according to very intensive BFM NHL protocols has not been investigated. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Jelena Roganovic, Ernest Bilic, Ljubica Rajic, Ranka Femenic Source Type: research

Outcomes in Refractory Aggressive Diffuse Large B Cell Lymphoma (DLBCL): Results from the International SCHOLAR-1 Study
Although patients with relapsed/refractory DLBCL have heterogeneous outcomes to subsequent therapy, patients with chemorefractory disease (r-DLBCL) have a worse prognosis. SCHOLAR-1 is a patient-level meta-analysis designed to assess outcomes in r-DLBCL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Michael Crump, Sattva Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Mohamed Ahmed, Brian Link, Annette Hay, James Cerhan, Liting Zhu, Sami Boussetta, Lei Feng, Matthew Maurer, Lynn Navale, Jeffrey Wiezorek, William Go, Christian Gisselbrecht Source Type: research

Ongoing Complete Remissions in ZUMA-1: A Phase 1-2 Multicenter Study of KTE-C19 (Anti-CD19 CAR T Cells) in Patients with Refractory Aggressive B Cell Non-Hodgkin Lymphoma
Outcomes in chemorefractory DLBCL are homogeneous and poor (ORR of approximately 26%, median overall survival of 6-7 months) and there is significant unmet need for effective therapies in this patient population. A National Cancer Institute (NCI) study using anti-CD19 CAR T cells with CD28 and CD3 ζ signaling domains showed durable remissions in patients with relapsed/refractory advanced B cell malignancies. KTE-C19 uses the same anti-CD19 construct as the NCI, manufactured using a streamlined 6- to 8-day process. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Sattva Neelapu, Frederick Locke, Nancy Bartlett, Tanya Siddiqi, Julio Chavez, Chitra Hosing, Amanda Cashen, Lihua Budde, Adrian Bot, John Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, Jeff Wiezorek, William Go Source Type: research

The Genetics of Nodal Marginal Zone Lymphoma
Nodal marginal zone lymphoma (NMZL) is a rare indolent B-cell tumor that is distinguished from splenic marginal zone lymphoma (SMZL) by the different pattern of dissemination. NMZL still lacks distinct markers and remains orphan of specific cancer gene lesions. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Valeria Spina, Hossein Khiabanian, Monica Messina, Sara Monti, Luciano Cascione, Alessio Bruscaggin, Elisa Spaccarotella, Antony Holmes, Luca Arcaini, Marco Lucioni, Fabrizio Tabb ò, Sakellarios Zairis, Fary Diop, Michaela Cerri, Sabina Chiaretti, Robert Source Type: research

Enteroviral Infection in Patients Treated with Rituximab for Non Hodgkin Lymphoma: a Case Series and Review of the Literature
The chimeric anti-CD20 monoclonal antibody rituximab is widely used for the treatment of B-cell lymphoproliferative disorders as well as for autoimmune diseases. Rituximab induces depletion of the peripheral B cell pool, leading to hypoglobulinemia which results in decreased antibody response to infections. Enteroviral infection can cause life-threatening meningoencephalitis and other systemic chronic syndromes in immune deficient patients (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Sigal Grisariu, Pia Raanani, Ora Paltiel, Oren Pasvolsky, Iuliana Vaxman, Moshe Gatt, Shlomo Elias, Batia Avni, Ariella Arad Source Type: research

The BET Bromodomain Inhibitor (BETi) OTX015 (MK-8628) Upregulates miR-96-5p in Diffuse Large B-Cell Lymphomas (DLBCL)
Aberrant changes in microRNAs (miRNAs), contribute to lymphomagenesis and represent potential therapeutic targets. OTX015 (MK-8628) has demonstrated preclinical and clinical activity in haematological tumours. To better understand the mechanism of action of OTX015 we studied its effects on miRNAs in lymphomas. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Afua Mensah, Luciano Cascione, Eugenio Gaudio, Elena Bernasconi, Chiara Tarantelli, Andrea Rinaldi, Riccardo Bomben, Valter Gattei, Anastasios Stathis, Emanuele Zucca, Ivo Kwee, Francesco Bertoni Source Type: research

Human V δ1+ γδ Peripheral T-Cell Lymphoma/Leukemia are Derived from Natural Killer T (NKT) Cells and Might be Treated with Blocking Anti-CD1d Antibody
Peripheral T-cell lymphomas (PTCL) are a heterogeneous entity of neoplasms with poor prognosis, lack of effective therapies, and a largely unknown pathophysiology. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Emmanuel Bachy, Mirjam Urb, Shilpi Chandra, R émy Robinot, Gabriel Bricard, Simon de Bernard, Alexandra Traverse-Glehen, Sophie Gazzo, Olivier Blond, Archana Khurana, Lucile Baseggio, Tayla Heavican, Martine Ffrench, Giuliano Crispatzu, Paul Mondière, A Source Type: research

Survival Impact of Serum Albumin (SA) in Patients with Acquired Immunodeficiency Syndrome (AIDS) Related Non-Hodgkin's Lymphomas
Despite effective combination antiretroviral therapy for HIV, there is still increased incidence of Acquired Immunodeficiency Syndrome (AIDS) related Non-Hodgkin lymphomas (NHLs). AIDS related NHLs represent a challenge for the practicing oncologist. Prognostic factors have been shown to be useful to risk stratify the disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Joseph Clara, Samir Dalia, Bijal Shah, Celeste Bello, Paul Chervenick, Luis Miguel Juarez Salcedo, Mohamed Kharfan-Dabaja, Lubomir Sokol, Eduardo Sotomayor, Julio Chavez Source Type: research

Long-Term Follow-Up of Primary Intestinal Aggressive Lymphomas Treated with mNHL-BFM-90
The primary intestinal aggressive lymphomas (PIAL) account about 70% of all intestinal lymphomas. Among them, diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) is the most frequent. R-CHOP chemotherapy can induce favorable results for localized-stage. However, the presence of adverse factors (AF) and advanced stages decrease the efficacy of this therapy: 5-year progression-free survival (PFS) and overall survival (OS) are about 50%. Due to the rarity PIAL the optimal treatment strategy for this patients (pts) remains unknown. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Evgeniy Zvonkov, Nelli Gabeeva, Anna Sidorova, Anna Morozova, Olga Gavrilina, Hunan Julhakyan, Darya Koroleva, Alla Kovrigina, Tatyana Obukhova, Elena Parovichnikova, Valeriy Savchenko Source Type: research

Targeting mTOR/PI3K in Primary CNS Lymphoma (PCNSL)
The prognosis of PCNSL remains worse than that of other diffuse-large B-cell lymphomas. Thus, there is a big need for further therapeutic improvement. Dysregulation of various cellular pathways, such as NFkB, toll-like receptor or B-cell receptor signaling have been reported in PCNSL and constitute a potential therapeutic target. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Agnieszka Korfel, Elisabeth Schorb, Uwe Schlegel, Sa ša Dimitrijević Dimitrijević, Saana D'Allonzo, Martin Dreyling, Ullrich Herrlinger, Philipp Kiewe Source Type: research

RELINFO - Brazilian Network for Lymphoma Registry in Rio de Janeiro: Preliminary Results
There are few data in the incidence, monitoring and prognosis of lymphomas patients in Brazil. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Leonardo Gomes, Adriana Scheliga, Marcio Hori, Monica Prexedes, Fernando Monteiro, Marilza Magalh ães, Rita Spariz, Kellen Blanco, Luciana Conti, Glaucia Guasti, Solange Elehep Source Type: research

Novel BRD4-Degrading Proteolysis Targeting Chimera (PROTACs) Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma (MCL) Cells
MCL cells exhibit chronic-active BCR signaling and downstream pro-growth and pro-survival NFkB activity. Ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase (BTK) yields high overall response rate in relapsed/refractory MCL, but approximately 40% of patients demonstrate primary refractory/resistant disease. Mutations in CARD11/IKBKB/TRAF2/BIRC3/NIK or in B-cell receptor (BCR) signaling induce activity of the classical or alternative NFkB pathway, conferring resistance to ibrutinib in MCL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Kapil Bhalla, Baohua Sun, Warren Fiskus, Liang Zhang, Dyana Saenz, Christopher Mill, Michael Wang Source Type: research

Myc+ Single-Hit Lymphoma Patients had Benefit from Dose-Intensified Chemotherapy
B-cell lymphomas with c-MYC rearrangement characterized by aggressive clinical behavior and poor prognosis when R-CHOP-21 is used. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Anna Misyurina, Elena Baryakh, Sergey Kravchenko, Alla Kovrigina, Tatyana Obukhova, Vsevolod Misyurin, Jana Mangasarova, Lubov Plastinina, Ekaterina Nesterova, Aminat Magomedova, Ekaterina Penskaya, Hunan Julhakyan, Andrey Vorobiev Source Type: research

Chemotherapy of Primary Mediastinal B-Cell Lymphoma
Primary mediastinal B-cell lymphoma (PMBCL) amounts from 0,9 to 4% of Non-Hodgkin Lymphomas. Predominantly suffer young women. All relapses in PMBCL occur as early events. Taking into account unfavorable prognosis in case of relapse or progression of PMBCL (2-year overall survival (OS) is about 15% [Kurvilla J., 2008]), it is necessary to achieve a complete remission (CR) in first line treatment. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Jana Mangasarova, Aminat Magomedova, Ekaterina Nesterova, Hunan Julhakyan, Sergey Kravchenko Source Type: research

Anaplastic Large Cell Lymphoma in Adults: Results and New Approach of Treatment
Anaplastic Large Cell Lymphoma (ALCL) represents subgroupe of peripheral T-cell lymphoma and constitutes 10-12% of this group. According to WHO 2008 classification two types depending on presence of ALK gene rearrangement subdivide ALCL: ALK-positive (ALCL ALK+) and ALK-negative (ALCL ALK-). ALCL ALK+ has a favorable prognosis with CHOP in patients without adverse prognostic factors and event free survival (EFS) reaches 70-75%. ALCL ALK- has worse treatment results: when using CHOP overall survival (OS) and EFS does not reach more than 50%. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Liliia Gorenkova, Elizaveta Klebanova, Ekaterina Penskaya, Hunan Julhakyan, Sergey Kravchenko, Valeriy Savchenko Source Type: research

The High Efficiency of AutoSCT in the Treatment of Refractory Follicular Lymphoma (FL): Results of the First Russian Prospective Study
FL represents one of the most frequent type of lymphomas: about 22% of non-Hodgkin lymphomas in Russia. 20% of patients (pts) are refractory to conventional R-CHOP therapy with dismal outcome. In cases with progressive tumor on induction therapy, autoSCT allows to increase the overall (OS) and progression-free survival (PFS). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Ekaterina Nesterova, Sergey Kravchenko, Jana Mangasarova, Vladimir Vorobyev, Eduard Gemdzhian, Hunan Julhakyan, Andrey Vorobyev, Valery Savchenko Source Type: research

Leukemization of Follicular Lymphoma: Diagnostic Features and Clinical Course of a Rare Form of the Disease
Follicular lymphoma is a frequent lymphoid neoplasm, accounting for 22 percent of all non-Hodgkin's lymphoma in Russia. At diagnosis, some patients with FL manifest a detectable leukemic phase – leukemization (FL-LP), but this feature has been seldom described and has a poor prognosis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Ekaterina Nesterova, Alla Kovrigina, Jana Mangasarova, Lybov Plastinina, Tatyana Obukhova, Eduard Gemdzhian, Hunan Julhakyan, Ivan Vorobyev, Sergey Kravchenko Source Type: research

Immune Cell Modulations in Nordic FL Patients After Lenalidomide in the SAKK 35/10 Trial
Follicular lymphoma (FL) is although responsive to various therapies considered incurable. Rituximab is known to have improved outcome, which seems to be accentuated if combined with lenalidomide. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Sandra Lockmer, Åsa Jeppsson-Ahlberg, Birgitta Sander, Eva Kimby, Björn Wahlin Source Type: research